5 results
The objectives of this open-label study are to evaluate the efficacy (GL-3 clearance), pharmacokinetics (PK), and safety parameters (including immunogenicity) for 2 alternative dose regimens of Fabrazyme (0.5 mg/kg every 2 weeks [q2w] and 1.0 mg/kg…
The primary objectives of this study are: * To characterize the effects of 150 mg and 450 mg of AT1001 administered 2 hours before administration of agalsidase on the safety and plasma pharmacokinetics of agalsidase in subjects with Fabry Disease*…
In this study, we will investigate how quickly and to what extent etrumadenant is absorbed, transported, and eliminated from the body. For this study, etrumadenant is radioactively labelled with carbon 14 (14C). In this way, etrumadenant can be…
Primary objectives:- Determine the value of fluorescence imaging-guided surgery under ambient light conditions for the identification of hybrid tracer-containing SNs as seen on preoperative imaging.Secondary objectives:- Determine the value (…
The aim of this proof-of-concept study is to investigate the feasibility of SLNB in thyroid carcinoma and optimize 68Ga-tilmanocept PET/CT the imaging protocol.